Should all stroke patients receive tissue plasminogen activator therapy, despite mild or improving symptoms?

Nature Clinical Practice Cardiovascular Medicine

Volumn 3, Issue 4, 2006, Pages 184-185

  Lyden, Patrick D ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Ischemic stroke; Tissue plasminogen activator

Indexed keywords

TISSUE PLASMINOGEN ACTIVATOR;

BLOOD CLOT LYSIS; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; COLLATERAL CIRCULATION; DETERIORATION; DRUG EFFICACY; DRUG INDICATION; FIBRINOLYTIC THERAPY; HEMODILUTION; HOSPITALIZATION; HUMAN; HYPERTENSION; HYPOVOLEMIA; NEUROLOGIC DISEASE; OUTCOMES RESEARCH; PATIENT SELECTION; PRIORITY JOURNAL; RATING SCALE; SCORING SYSTEM; SHORT SURVEY; SYMPTOMATOLOGY;

AGED; CEREBROVASCULAR ACCIDENT; CONFIDENCE INTERVALS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; FIBRINOLYTIC AGENTS; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; NEEDS ASSESSMENT; PROBABILITY; REFERENCE VALUES; RETROSPECTIVE STUDIES; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; SURVIVAL RATE; TISSUE PLASMINOGEN ACTIVATOR; TREATMENT OUTCOME;

EID: 33645384921     PISSN: 17434297     EISSN: 17434300     Source Type: Journal    
DOI: 10.1038/ncpcardio0511     Document Type: Short Survey

References (5)

1. Caplan L et al. (1997) Should thrombolytic therapy be the first-line treatment for acute ischemic stroke? N Engl J Med 337: 1309-1310
2. Hacke W et al. (2004) Association of outcome with early stroke treatment: Pooled analysis of ATLANTIS, ECASS, and NINDS rt-PA stroke trials. Lancet 363: 768-774
3. Barber PA et al. (2001) Why are stroke patients excluded from TPA therapy? Neurology 56: 1015-1020
4. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group (1995) Tissue plasminogen activator for acute ischemic stroke. N Engl J Med 333: 1581-1588
5. Lyden PD (2005) Thrombolytic Therapy for Acute Stroke. Totowa: Humana Press